Cancer Research March 2011
Gap Junction–Mediated Import of MicroRNA from Bone Marrow Stromal Cells Can Elicit Cell Cycle Quiescence in Breast Cancer Cells.
Monday, March 14, 2011
Whole genome sequencing of single tumor cells: A method to infer Tumor evolution? Nature 2011
Tumour evolution inferred by single-cell sequencing
Nature (2011) doi:10.1038/nature09807
Received 25 May 2010 Accepted 07 January 2011 Published online 13 March 2011
Nature (2011) doi:10.1038/nature09807
Received 25 May 2010 Accepted 07 January 2011 Published online 13 March 2011
Annexin-1 interacts with NEMO and RIP1 to constitutively activate IKK complex and NF-κB: implication in breast cancer metastasis.
Oncogene. 2011 Mar 7. [Epub ahead of print]
Annexin-1 interacts with NEMO and RIP1 to constitutively activate IKK complex and NF-κB: implication in breast cancer metastasis.
publication, 7 March 2011; doi:10.1038/onc.2011.28.
Annexin-1 interacts with NEMO and RIP1 to constitutively activate IKK complex and NF-κB: implication in breast cancer metastasis.
publication, 7 March 2011; doi:10.1038/onc.2011.28.
Friday, March 11, 2011
Breast cancer: Luminal cells with an identity crisis
Breast cancer: Luminal cells with an identity crisis
Gemma K. Alderton
Abstract
Inherited mutations in BRCA1 seem to specifically increase the risk of developing basal-like breast cancers; so, Proia and colleagues investigated how BRCA1 might promote the formation of this subtype of breast cancer.Using samples from reduction mammoplasty (BRCA1+/+) and prophylactic mastectomy from individuals with BRCA1 mutations (BRCA1mut/+), Proia and colleagues transformed cell suspensions with four tumorigenic genes (TP53R175H, CCND1, PI3KCA and KRASG12V) that are
Gemma K. Alderton
Abstract
Inherited mutations in BRCA1 seem to specifically increase the risk of developing basal-like breast cancers; so, Proia and colleagues investigated how BRCA1 might promote the formation of this subtype of breast cancer.Using samples from reduction mammoplasty (BRCA1+/+) and prophylactic mastectomy from individuals with BRCA1 mutations (BRCA1mut/+), Proia and colleagues transformed cell suspensions with four tumorigenic genes (TP53R175H, CCND1, PI3KCA and KRASG12V) that are
Hallmarks of cancer: the next generation. Weinberg, Hanahan. Cell 2011. PDF
Cell. 2011 Mar 4;144(5):646-74.
Los hallmarks del cáncer propuestos desde hace varios años por Weinberg incorporan ahora otras características ya propuestas por otros múltiples veces como la inflamación, la necrosis, las alteraciones metabólicas entre otras.
Cell. 2011 Mar 4;144(5):646-74.
Los hallmarks del cáncer propuestos desde hace varios años por Weinberg incorporan ahora otras características ya propuestas por otros múltiples veces como la inflamación, la necrosis, las alteraciones metabólicas entre otras.
Tuesday, March 08, 2011
Thursday, March 03, 2011
Special issue of Nature Reviews Clinical Oncology on personalized medicine, includes essay from L. Hood, S. Friend:
OPINION:
Predictive, personalized, preventive, participatory (P4) cancer medicine
Leroy Hood & Stephen H. Friend About the authors
top of page
Abstract
Medicine will move from a reactive to a proactive discipline over the next decade—a discipline that is predictive, personalized, preventive and participatory (P4). P4 medicine will be fueled by systems approaches to disease, emerging technologies and analytical tools. There will be two major challenges to achieving P4 medicine—technical and societal barriers—and the societal barriers will prove the most challenging. How do we bring patients, physicians and members of the health-care community into alignment with the enormous opportunities of P4 medicine? In part, this will be done by the creation of new types of strategic partnerships—between patients, large clinical centers, consortia of clinical centers and patient-advocate groups. For some clinical trials it will necessary to recruit very large numbers of patients—and one powerful approach to this challenge is the crowd-sourced recruitment of patients by bringing large clinical centers together with patient-advocate groups.
FULL TEXT:
http://www.nature.com/nrclinonc/journal/v8/n3/full/nrclinonc.2010.227.html
Predictive, personalized, preventive, participatory (P4) cancer medicine
Leroy Hood & Stephen H. Friend About the authors
top of page
Abstract
Medicine will move from a reactive to a proactive discipline over the next decade—a discipline that is predictive, personalized, preventive and participatory (P4). P4 medicine will be fueled by systems approaches to disease, emerging technologies and analytical tools. There will be two major challenges to achieving P4 medicine—technical and societal barriers—and the societal barriers will prove the most challenging. How do we bring patients, physicians and members of the health-care community into alignment with the enormous opportunities of P4 medicine? In part, this will be done by the creation of new types of strategic partnerships—between patients, large clinical centers, consortia of clinical centers and patient-advocate groups. For some clinical trials it will necessary to recruit very large numbers of patients—and one powerful approach to this challenge is the crowd-sourced recruitment of patients by bringing large clinical centers together with patient-advocate groups.
FULL TEXT:
http://www.nature.com/nrclinonc/journal/v8/n3/full/nrclinonc.2010.227.html
Subscribe to:
Posts (Atom)